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Abstract Previous studies have shown that radiofre-
quency thermal ablation (RFA) of uterine ﬁbroids through a
percutaneous ultrasound (US)-guided procedure is an
effective and safe minimally invasive treatment, with
encouraging short-term results. The aim of this study was to
assess the results in terms of volume reduction and clinical
symptoms improvement in the midterm follow-up of ﬁb-
roids with a diameter of up to 8 cm. Eleven premenopausal
females affected by symptomatic ﬁbroids underwent per-
cutaneous US-guided RFA. Symptom severity and reduc-
tion in volume were evaluated at 1, 3, 6, 9, and 12 months.
The mean symptom score (SSS) before the procedure was
50.30 (range 31.8–67.30), and the average quality of
life (QOL) score value was 62 (range 37.20–86.00). The
mean basal diameter was 5.5 cm (range 4.4–8) and
the mean volume was 101.5 cm
3 (range 44.58–278 cm
3).
The mean follow-up was 9 months (range 3–12 months).
The mean SSS value at the end of the follow-up was 13.38
(range 0–67.1) and the QOL 90.4 (range 43.8–100). At
follow-up the mean diameter was 3.0 cm (range 1.20–
4.5 cm), and the mean volume was 18 cm
3 (range 0.90–
47.6 cm
3). In 10 of 11 patients we obtained total or partial
regression of symptoms. In one case the clinical manifes-
tations persisted and it was thus considered unsuccessful. In
conclusion, US-guided percutaneous RFA is a safe and
effective treatment even for ﬁbroids up to 8 cm.
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Introduction
Uterine ﬁbroids are the most common pelvic tumor of the
female genital tract and tend to increase with age. The most
frequent clinical symptoms are menorrhagia, pelvic pain, a
feeling of pelvic fullness, and infertility [1]. In the last
decades, social and cultural changes, along with techno-
logical improvements in medicine, have increased the need
for women to retain their uterus, above all when symp-
tomatic uterine ﬁbroids are diagnosed at reproductive age
and women wish to have children [2, 3]. Hence, a large
variety of less invasive alternatives to hysterectomy has
been developed [4], such as myomectomy [5], uterine
artery embolization (UAE) [6–8], cryomyolisis [9–11],
high-intensity focused ultrasound (HIFU) [12–14], and
recently radiofrequency thermal ablation (RFA) [15–19].
This study reports our experience on a group of patients
whose uterine ﬁbroids were treated using percutaneous
ultrasound-guided RFA. Patients with ﬁbroids up to 8 cm
were included.
Materials and Methods
Between March 2006 and February 2008, 11 consecutive
premenopausal women with symptomatic uterine ﬁbroids
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oral contraceptives, and anti-inﬂammatory drugs) were
recruited by the gynecologist at our hospital in this study to
be submitted to RFA treatment.
Our inclusion criteria were women who had completed
childbearing and absolutely declined hysterectomy. Exclu-
sion criteria were the presence of more than three ﬁbroids or
of one ﬁbroid[8 cm, a gynecological malignant pathology
in the past 5 years, a pelvic inﬂammatory disease, abnormal
coagulation tests, breastfeeding, and current pregnancy. All
patients were counseled on the potential risks and beneﬁts
of the procedure before giving their own written consent.
The Institutional Review Board granted authorization to
collect data prospectively and approved the study.
All women were assessed regarding the severity of
symptoms and the quality of life (QOL) by use of the
Uterine Fibroids Symptom and Quality of Life question-
naire (UFS-QOL). This questionnaire consists of eight
questions about the severity of the symptoms and 29
health-related quality of life questions. Two scores are
calculated, one assesses the symptoms (SSS) and the other
the QOL [20]. Raw scores were converted to a transformed
score using the following formula: transformed scor-
e = (raw score - 8)/32 9 100. The transformed score
varied from 0 to 100, with 100 being the most severely
symptomatic. Such clinical evaluation was also repeated
3 months after treatment, at the same time as the instru-
mental evaluation.
The pretreatment evaluation was performed with trans-
vaginal and suprapubic ultrasound (US) to determine the
number, dimensions, and location of the myomas. The
uterine ﬁbroids volume was calculated by the following
formula: volume = 0.5233 9 D1 9 D2 9 D3, where D1
is the longitudinal dimension, D2 is the anterior-posterior
dimension, and D3 is the transverse one [21].
Procedures were performed at the day hospital and
patients were under moderate sedation (intravenous
administration of 1–3 mg midazolam, 1–3 mg fentanyl,
and 50–120 mg propofol) in the presence of the anesthetist.
All patients received an antibiotic prophylaxis according to
an ‘‘ultra-short-term antibiotic prophylaxis’’ scheme with a
preprocedural intravenous injection of 1 g of cefazolin to
obtain a hematic peak concentration of the medicine at the
moment of necrosis.
We used the Le Veen coaxial needle electrode, 3.5 or
4 cm (Boston Scientiﬁc, Natick, MA, USA), with 10–14
hooks at the extremity, which were opened during the
procedure. In the two patients with ﬁbroids [6 cm, two
needle deployments were performed to obtain a volume of
necrosis comparable to the volume of ﬁbroids. The needle
electrode was connected to a generator (RF 3000 Genera-
tor; Boston Scientiﬁc) that operates at a maximum power
of 250 W and at temperatures ranging from 15 to 125C;
the generator displays the tissue impedance characteristics
as well as the ablation power and time. The selected tem-
perature to reach within the tissue was 85C and the gen-
erator automatically adjusted the power to maintain that
temperature (150 W).
Real-time suprapubic US was used to perform the pro-
cedure transpelvically. To avoid hemorrhagic complica-
tions, cauterization of the needle track was obtained at the
end of the procedure by setting the generator at 10 W of
power while removing the needle.
We evaluated the presence of both intra- and postpro-
cedural minor and major complications in all patients.
Minor complications were deﬁned as temporary and self-
limiting symptoms requiring no therapy or normal therapy
without any clinical sequelae. Major complications were
deﬁned as those requiring further interventions and/or
hospitalization.
Technical success was assessed 1 day after the procedure
by suprapubic US with the administration of a 2.5-ml bolus
of second-generation contrast medium (Sonovue; Bracco,
Milan, Italy), followed by 10 ml of physiological solution.
Contrast-enhanced ultrasound (CEUS) exams were per-
formed with Technos MPX (Esaote Biomedica, Genoa,
Italy) and IU 22 (Philips; Best, The Netherlands) ultrasound
equipment. Instrumental evaluation of results at 1, 3, 6, 9,
and 12 months after treatment was performed by CEUS and
the following criteria were assessed: the presence of a
necrotic area—deﬁned as a hyphoechoic area without
contrast medium enhancement—and diameter reduction.
Statistical analysis was performed with GraphPad Prism
version 3.00 for Windows (GraphPad Software, San Diego,
CA, USA). Statistical signiﬁcance was set at P\0.05.
The aims of the study were, ﬁrst, to assess the feasibility
of RFA of uterine ﬁbroids up to 8 cm and, second, to assess
SSS and QOL improvements and volume shrinkage at
midterm follow-up.
Results
Results are summarized in Table 1. Eleven premenopausal
women (mean age 40.4; range 27–51), with a single uterine
ﬁbroid in 10 cases and two ﬁbroids in 1 case (of which only
the largest one was treated), underwent RFA. In one case
the ﬁbroid had an anterior submucosal position, in one case
a posterior intramural one, in four cases an anterior intra-
mural position, in four cases a fundic one, and in one case
it was located in the left parietal. Patients showed symp-
toms such as pelvic pain (10/11), menorrhagia (8/11), and a
feeling of pelvic fullness (1/11) and they were not
responsive to medical therapies.
The mean SSS value before the procedure was 50.30
(range 31.8–67.30), and the mean QOL score value was 62
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treated ﬁbroids was 5.5 cm (range 4.4–8 cm) and the mean
volume was 101.5 cm
3 (range 44.58–278 cm
3).
Needle insertion inside the ﬁbroid was carried out
without any problems and enabled the maximum opening
of the hooks (as visualized by US with two orthogonal
Table 1 Age, mean diameter
and volume reduction, and
changes in SSS and QOL in 11
patients
Patient ID
and age
Parameter Time (month)
01 36 91 2
(A) 42 Diameter (cm) 5 4.20 3.10 2.20 2.00 2.00
Volume (cm
3) 65.42 38.77 15.59 5.57 4.19 4.19
SSS 44.20 – 20.20 6.10 2.00 00
QOL 66.20 – 84.30 98.00 100.00 100.00
(B) 42 Diameter (cm) 4.90 3.80 3.70 3.10 1.30 1.20
Volume (cm
3) 61.57 28.72 26.51 15.59 1.15 0.90
SSS 67.30 – 38.00 8.20 00 00
QOL 76.30 – 90.20 95.30 99.00 100.00
(C) 39 Diameter (cm) 4.40 3.70 3.30 2.00 1.90 1.90
Volume (cm
3) 44.58 26.51 18.81 4.19 3.59 3.59
SSS 52.40 – 35.30 00 00 00
QOL 53.90 – 77.00 99.10 99.00 99.00
(D) 40 Diameter (cm) 5.2 4.20 3.60 3.10 3.10 –
Volume (cm
3) 73.58 38.77 24.42 15.59 15.59 –
SSS 31.80 – 10.00 3.20 3.00 –
QOL 37.20 – 65.30 89.10 92.00 –
(E) 42 Diameter (cm) 4.5 3.90 3.20 2.80 2.60 –
Volume (cm
3) 47.69 31.04 17.15 11.49 9.20 –
SSS 40.30 – 8.00 2.00 1.90 –
QOL 86.00 – 90.00 100.00 100.00
(F) 42 Diameter (cm) 4.8 4.1 3.2 – – –
Volume (cm
3) 58.58 31.04 18.81 – – –
SSS 47.2 – 26.00 – – –
QOL 63.92 – 86.30 – – –
(G) 51 Diameter (cm) 5.3 5.3 5.3 – 3 –
Volume (cm
3) 78 78 78 – 14 –
SSS 50.6 35.20 23 – 23 –
QOL 70.1 78 84.30 – 84.30 –
(H) 45 Diameter (cm) 8.1 4.8 4.5 4.5 – –
Volume (cm
3) 278 57 47 47 – –
SSS 47 0 0 0 – –
QOL 55.1 100 100 100 – –
(I) 27 Diameter (cm) 6 – – 3.9 3.9 3.5
Volume (cm
3) 113 – – 31 31 22
SSS 40.5 – – 18 18 18
QOL 76.3 – – 89.20 89.20 89.20
(L) 41 Diameter (cm) 7.06 5 5 5 3.03 3.03
Volume (cm
3) 184 65 65 65 14.60 14.60
SSS 65 17 17 17 0 0
QOL 53 87.8 87.8 87.8 100 100
(M) 34 Diameter (cm) 6 4.5 4.5 Hysterectomy
Volume (cm
3) 113 47.6 47.6
SSS 67.1 67.1 67.1
QOL 43.8 43.8 43.8
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123incidents). The operative time ranged from 15 to 25 min
(average 20 min). No intra- or postoperative complications
occurred. In two cases the patients complained of medium
abdominal pain, which was treated with a NSAID: in one
case we observed some ﬂuid in the pelvic pouch on the
postprocedural suprapubic US, which disappeared at
the following US checkup. Patients were admitted to the
gynecologic day hospital in the morning and discharged
home in the evening.
Technical success was obtained in all patients (100%):
CEUS studies revealed complete ablation of the ﬁbroids,
showing a hypoechoic vascular area due to necrosis. The
mean US follow-up was 9 months (range 3–12 months); at
the last checkup the mean SSS value was 13.38 (range
0–67.1) and the mean QOL was 90.4 (range 43.8–100); the
mean diameter was 3.0 cm (range 1.20–4.5 cm) and the
mean volume 18 cm
3 (range 0.90–47.6 cm
3). The mean
QOL value recorded was 77.4 at 1 month (4 cases), 80.9 at
3 months (10 cases), 95 at 6 and 9 months (8 cases), and 97
at 12 months (5 cases) (Fig. 1). At the last checkup 6 of 11
patients (54%) were asymptomatic, while for 4 patients
(36%) the symptoms had clearly decreased. In 10 of 11
cases (91%) the SSS and QOL values improved. In nine
patients (81%) the ﬁbroid volume reduction rate was always
[65% (min 65%–max 98%) at 6-, 9-, and 12-month follow-
up. In two patients, for whom we only had the 3-month
follow-up, the volume reduction was 58 and 68%, respec-
tively. The mean volume reduction was 46.9% at 1-month
checkup (10 cases), 53% at 3 months (10 cases), 79% at
6 months (8 cases), 86% at 9 months (8 cases), and 91% at
12-month follow-up (5 cases) (Fig. 2). In one case only
(9%; patient M, Table 1), even though the ﬁbroid volume
decreased, neither the pain nor the menorrhagia showed any
sign of improvement, and the QOL and SSS values
remained unchanged. Hence the patient underwent hyster-
ectomy. During hysterectomy no adhesions were found and
histology showed two necrotic adjacent nodules at the
endometrial surface due to the previous RFA procedure.
We did not observe any revascularization phenomena in
the treated ﬁbroids, nor did we need to repeat a RFA
treatment.
Discussion
In a literature review (Table 2), we observed that 70
women (mean age 42.8) underwent RFA of uterine ﬁb-
roids, 29 (42%) by laparoscopy and 41 (58%) percutane-
ously [15–19]. The RITA Medical System needle electrode
was the most used. These studies have taken into account
no more than three tumors at a time or tumors \6c m
because RFA needles can produce at least a 5- to 6-cm
necrotic area in a single deployment.
In 2005 Bergamini et al. [18] conducted the ﬁrst clinical
experiment in which 18 patients with symptomatic uterine
ﬁbroids underwent an RFA treatment by laparoscopy. The
study highlighted the ablative efﬁcacy (for nine patients
the volume decreased by 85%, the SSS decreased, and the
QOL improved) and the absence of immediate or late
complications. Subsequent studies by Ghezzi et al. [15] and
Milic et al. [17] showed similar results as far as volume
reduction and symptoms improvements are concerned: in
the study by Ghezzi et al. [15], the mean follow-up was
24 months (range 12–36 months), with a 70% volume
reduction of treated ﬁbroids at 6 months and stable results
at the 3-year follow-up. Kim et al. [19] treated 35 patients
with percutaneous RFA after having performed UAE to
improve its clinical efﬁcacy. Six months after treatment,
the mean volume reduction was 56%, and at the same time
symptoms had improved. In one case only the procedure
was not successful [15]; in two cases [15, 17] the patients
underwent hysterectomy after RFA treatment because of
pain not responsive at 5 and 12 months. Early or late major
complications did not occur in any series.
Our personal series conﬁrms the results published in
the literature, showing that this treatment can be feasible
and effective in reducing volume and improving symp-
toms. For 9 of 11 patients we obtained a shrinkage rate
[65% at the 6-month follow-up. The following control at
12 months conﬁrmed stability and revealed further vol-
ume reduction. Only one case was unsuccessful, because
of persisting pain, hence the patient underwent hysterec-
tomy. In our experience, considering the benign pathology Fig. 1 Changes in QOL during follow-up
Fig. 2 Changes in volume during follow-up
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maximum instrumental 12-month follow-up. Moreover,
Ghezzi et al. [14] over a follow-up of 3 years, did not
register any major modiﬁcations in volume reduction or
symptom improvement.
In our series, in the two patients with a ﬁbroid larger
than 6 cm we obtained a considerable volume reduction
(90%), which proved to be stable at the following checkup
12 months later. In the patient affected by an 8-cm ﬁbroid,
the 6-month follow-up showed a shrinkage of 84%. How-
ever, it has not been possible to assess the stability over
time, as no subsequent checkups were available. In both
cases we performed two needle positionings without any
peri- or postprocedural complications (see Fig. 3).
Table 2 Literature review
Reference N Technique Follow-up
(months)
Symptom Complication(s) Volume reduction
Bergamini et al.
2005 [18]
18 Laparoscopy 10 SSS 4.7, QOL 100,
at 6 months
2 abdominal pain 83% at 9 and
12 months
Ghezzi et al.
2007 [15]
18 ? 7 Laparoscopy 24 SSS 4.7, QOL 99.1,
at 6 months
1 hysterectomy at 1 year 68.8% at 6 months,
77.9% at 1 year,
83.9% at 3 years
Milic et al. [17] 4 Laparoscopy 3 Symptom improvement,
2/4
1 technical failure,
1 hysterectomy
at 5 months
Kim et al. [19] 35 Embolization ?
percutaneous RFA
6 QOL 17.4
at 6 months
1 urinary tract infection,
3 post-embolization
syndrome
56% at 6 months
Recaldini et al.
2007 [16]
6 Percutaneous RFA 7 SSS 4.2, QOL 97.5 82%
Note: N number of patients
Fig. 3 A 41-year-old woman
affected by a 7-cm symptomatic
uterine ﬁbroid. A B-mode US
shows a hypoechoic mass in the
uterus. B CEUS conﬁrms rich
vascularization inside the mass.
C B-mode US 6 months after
percutaneous RFA: the treated
ﬁbroid appears
nonhomogeneous and reduced
in size. D CEUS conﬁrmed a
huge area of necrosis with a
peripheral rim of enhancement
in a normal uterus without any
residual disease
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introduce the possibility of treating ﬁbroids up to 8 cm
without performing UAE before RFA. However, more
extensive studies, with both a larger number of patients and
a longer follow-up, should be conducted to prove the
results’ stability over time.
Both the transpelvic procedure and the needle insertion
at depth were performed using suprapubic US guidance,
which lowered the risk of lesion to nearby organs. CEUS is
able to show the presence of vital tissue during the follow-
up in order to recognize failures or recurrences early on
[22]. CEUS exams are fast and reliable at showing a per-
ilesional peripheral rim at 1 day, due to reactive hyperemy,
only partially recognizable at the 3-month checkup. At our
hospital we did not perform routine preprocedural imaging
or follow-up with MR as elsewhere [23–25], because MR
is not readily available at our institution for this purpose.
RFA represents a safe procedure with a low risk of
complications. In our study we did not encounter any major
complications, including bleeding, which can be success-
fully prevented by the use of a track ablation technique to
coagulate perimyoma vessels along the access path. It is
not possible to assess the risk of adhesions linked to ther-
mal lesions of the bowels, as our follow-up was so short.
Only with a longer follow-up would we be able to compare
such risk with that linked to laparoscopic thermal ablation
and traditional surgical techniques. From a technical point
of view injection of saline solution among the bowel loops
could be useful in some cases.
The larger cohort and longer follow-up of our series
compared to previous published papers conﬁrm the results
proving the treatment’s feasibility and its efﬁcacy in terms
of volume reduction and clinical symptom improvement. It
also introduces the possibility of treating larger ﬁbroids and
it highlights the technical feasibility of multiple needle
electrode placement without further peri- or postprocedural
complications. Nevertheless, these results are preliminary,
as the number of patients was restricted and the actual
follow-up time limited.
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